%0 Journal Article
%T <i>TP</i>53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma
%A Ligia Richter
%A Marcelo Buzzi
%A Carmela Dantas-Barbosa
%J International Journal of Clinical Medicine
%P 44-50
%@ 2158-2882
%D 2013
%I Scientific Research Publishing
%R 10.4236/ijcm.2013.412A1008
%X <p class=\"MsoNormal\">
	<span lang=\"EN-US\" style=\"font-family:Verdana;\">Osteosarcoma is a rare and highly
malignant tumor that usually affects adolescents and young adults. Despite current
management protocols, up to half of patients succumb to the disease. Moreover,
there is no well-characterized molecu</span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">lar marker for diagnosis and prognosis. </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53 alterations have been associated with a poor prognosis in
many cancers. The aim of this retrospective work was to find out whether </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53 functional status predicts response
to neoadjuvant chemotherapy and thus may help treatment decision for
osteosarcoma patients. Seventeen biopsies of osteosarcoma patients receiving
primary metotrexate, cisplatin and adryamicin chemotherapy followed by surgery
were analyzed. </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53
exons 5</span></span><span lang=\"EN-US\" style=\"font-family:Verdana;\">-</span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">9 mutations were
screened. Among 17 biopsies, 4 (23.5%) displayed </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53 mutations: 3 deletions and one single-nucleotide substitution.
The presence of </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53 gene mutation
does not correlate with resistance to chemo</span></span><span lang=\"EN-US\" style=\"font-family:Verdana;\">therapy according to histological
Rosen grade </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">and </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">nevertheless is associated with patient¡¯s age in a significant manner (p</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\" style=\"font-family:Verdana;\">&lt;</span><span lang=\"EN-US\"> </span><span lang=\"EN-US\"><span style=\"font-family:Verdana;\">0.05). The presence of non-mutated </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53 is not entirely specific for a good
prognosis. We found no evidence that </span><i><span style=\"font-family:Verdana;\">TP</span></i><span style=\"font-family:Verdana;\">53
mutations predict chemoresistance in osteosarcoma patients</span></span><span lang=\"EN-US\"> </span><span lang=\"EN-US\"
%K Osteosarcoma
%K Chemoresistance
%K &lt
%K i&gt
%K TP&lt
%K /i&gt
%K 53 Gene
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=41418